InDevR Launches 5’CapQ for Rapid Critical Quality Attribute Determination of mRNA-Based Vaccines

June 25, 2024 11:00 AM

New Kit Lets Vaccine Manufacturers Test 5′ Capping Efficiency at the Bench, With Answers in Less Than Two Hours BOULDER, CO / ACCESSWIRE / June 25, 2024 / InDevR Inc ., a leader in analytical solutions for vaccine in-process and quality control testing, is excited to announce the launch of 5'Cap Q for fast determination of 5' capping efficiency of mRNA. This ready-to-go, validated kit for the company's VaxArray Platform gives mRNA vaccine...

Read more

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

June 25, 2024 9:00 AM

IRVINE, CA / ACCESSWIRE / June 25, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in the Virtual Investor Closing Bell Series on Thursday, June 27, 2024 at 4:00 PM ET. As part of the event, Mr. Berman will discuss the Company's recently...

Read more

Product Creation Studio Partners With PatchClamp Medtech Inc. to Develop Revolutionary Dural Repair System

June 24, 2024 6:21 PM

SEATTLE, WA / ACCESSWIRE / June 24, 2024 / Product Creation Studio (PCS), a premier provider of engineering and design services, is excited to announce a new partnership with PatchClamp Medtech Inc. (PMI). This collaboration focuses on developing PatchClamp's novel dural repair graft placement system, designed to address the challenges of durotomy-perforations in the dura during cranial and spinal surgeries-which can lead to severe complications...

Read more

BioInvent Gains Patent for BI-1808 in China

June 24, 2024 8:30 AM

LUND, SWEDEN / ACCESSWIRE / June 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notice of allowance, informing the company that a patent application relating to the...

Read more

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

June 24, 2024 8:20 AM

This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes.This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS.Paridiprubart was selected following a competitive review process of multiple host-directed therapeutic candidates.TORONTO, ON / ACCESSWIRE / June 24, 2024 / Edesa Biotech,...

Read more

Eyam Announces Nicholas Franco Appointment to Board of Advisors

June 24, 2024 7:00 AM

Eyam is pleased to announce the appointment of Nicholas Franco to its Board of Advisors. Mr. Franco brings a wealth of experience and strategic vision from his extensive career in the pharmaceutical industry. Mr. Franco has held key executive level leadership positions in several prominent organizations, including his most recent role as Executive Vice President and Chief Business Development Officer at Actelion, a Janssen Pharmaceutical...

Read more

Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting

June 21, 2024 8:35 AM

enVVeno Medical Corporation (NASFAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that positive interim venous ulcer healing data showing significant clinical improvement from the SAVVE U.S. pivotal trial for the VenoValve will be presented today at the Society for Vascular Surgery 2024 Vascular Annual Meeting in Chicago. The data being presented includes...

Read more

Ondine Biomedical Inc - Steriwave now available through NHS Supply Chain

June 21, 2024 2:00 AM

Ondine Biomedical Inc. (LON:OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, is pleased to announce that its Steriwave® nasal photodisinfection is now available through the NHS Supply Chain, making it significantly easier for NHS hospitals in England and Wales to purchase. This marks the first time a light-activated antimicrobial has been available through the NHS Supply Chain, a national body which...

Read more

Luxor Scientific Unveils Cutting-Edge Testing Solutions to Combat Escalating Illicit Drug Crisis

June 20, 2024 2:00 PM

Luxor Scientific, a leader in scientific research, announces groundbreaking advancements in combatting the rise of deadly illicit drugs. Leveraging expertise in toxicology, Luxor has developed advanced testing solutions to address the nation's overdose crises associated with substances like bromazolam, tianeptine, xylazine, and nitazenes, providing healthcare professionals the information needed to develop more effective treatment...

Read more

Tharimmune Announces $2.08 Million Private Placement

June 20, 2024 8:00 AM

Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, developing lead candidate, TH104 for chronic pruritus in primary biliary cholangitis announced today that it has entered into a securities purchase agreement for the purchase and sale of an aggregate of 659,545 shares of its common stock (or common stock...

Read more

Alligator Bioscience to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024

June 20, 2024 2:20 AM

LUND, SWEDEN / ACCESSWIRE / June 20, 2024 / Alligator Bioscience (STO:ATORX)Primary endpoint of OPTIMIZE-1 trial was met, with Objective Response Rate (ORR) of 40.4% in 57 evaluable patientsUnprecedented Duration of Response (DoR) and a prolonged Overall Survival (OS)Further validation of data, following recent ASCO presentations and publication in The Lancet Oncology18-month survival follow-up data from OPTIMIZE-1 expected in late June...

Read more

Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million

June 20, 2024 1:20 AM

Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today announces the signature of an exclusive license agreement with Blanver, one of the leading and most trusted pharmaceutical company in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin American including, but not limited to Brazil, Mexico, Argentina and...

Read more

Bionoid Pharma Announces Agreement to Acquire AiMaverickIntel.com

June 18, 2024 11:00 AM

Bionoid Pharma, Inc. ("BINP") (OTC Pink:BINP) today announced that it has entered into a Letter of Intent to acquire AiMaverickIntel.com, a leading Audience Acquisition platform powered by Artificial Intelligence (AI). This strategic acquisition underscores BINP's interest in leveraging advanced technology to enhance audience engagement and acquisition strategies.This new agreement follows the cancellation of a previously announced agreement to...

Read more

Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study

June 18, 2024 9:00 AM

Lexaria Bioscience Corp. (NASDAQ:LEXX,)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has now hired a contract research organization ("CRO") to oversee execution of the Company's 12-week chronic study GLP-1-H24-4, (the "Study") which will evaluate various DehydraTECH-GLP-1 (glucagon-like peptide) formulations and other treatments with efficacy objectives of weight loss, blood sugar...

Read more

AbTherx Opens Antibody Discovery Technologies Research Center

June 18, 2024 6:00 AM

AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced the opening of its new antibody discovery technologies research center. The new state-of-the-art laboratory includes a multimillion-dollar investment in antibody discovery research automation and facilities to develop innovative therapeutics and transgenic mouse technologies."We are expanding our footprint in San...

Read more

Year-end Report 2023/2024

June 18, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / June 18, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Steadily increasing sales in the USASEK t Q4 23/24 Q4 22/23 May-April 23/24 May-April 22/23 Net sales 1,899 587 7,290 3,383 Operating profit (loss) -41,490 -37,208 -126,845 -110,457 Earnings per share after dilution -0.47 -0.81 -2.14 -3.18 Number of shares at the end of the period 84,055,560 45,741,450 84,055,560 ...

Read more

New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024

June 17, 2024 12:00 PM

IRVINE, CA / ACCESSWIRE / June 17, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that new interim venous ulcer healing data from the VenoValve U.S. pivotal trial will be presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting (VAM2024) being held June 18-22, 2024 in Chicago, IL. The presentation,...

Read more

Faro Health Inc. Appoints Vivian DeWoskin as Chief Strategy Officer

June 17, 2024 9:00 AM

Vivian joins Faro Health Inc. as the company aims to accelerate the growth and adoption of its market-leading SaaS platform for data-driven clinical development.SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Faro Health Inc., the leading SaaS platform for data-driven clinical development, is pleased to announce the appointment of Vivian DeWoskin as Chief Strategy Officer.Vivian joins the Faro Health team as the company looks to significantly...

Read more

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

June 17, 2024 8:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, reports positive Type C meeting feedback from the U.S. Food and Drug Administration (FDA) for its Phase 2 clinical trial with TH104, a proprietary transmucosal buccal film embedded with the approved, active compound nalmefene for moderate-to-severe pruritus or...

Read more

Hemogenyx Pharmaceuticals PLC Announces Operations Update

June 17, 2024 2:00 AM

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to provide an update on its ongoing activities and progress.1. HEMO-CAR-TClinical Trials Progress:Additional Clinical Trial Site: The Company has added an additional prestigious US medical center to its list of clinical trial sites. This will enhance the scope and expedite the timeline for the...

Read more